Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
Song Li, Wenbin Yu, Fei Xie, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 131
In situ self-assembly for cancer therapy and imaging
Jaewon Kim, Sung‐Kyu Lee, Yuri Kim, et al.
Nature Reviews Materials (2023) Vol. 8, Iss. 11, pp. 710-725
Closed Access | Times Cited: 118
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Y.L. Verschoor, Joris van de Haar, José G. van den Berg, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 519-530
Open Access | Times Cited: 49
Multifunctional Biomimetic Liposomes with Improved Tumor‐Targeting for TNBC Treatment by Combination of Chemotherapy, Anti‐Angiogenesis and Immunotherapy
Jinshuai Lan, Lixia Chen, Zhe Li, et al.
Advanced Healthcare Materials (2024)
Closed Access | Times Cited: 31
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
Jian‐Xian Lin, Yi-Hui Tang, Hua‐Long Zheng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Exploiting temporal aspects of cancer immunotherapy
Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 480-497
Closed Access | Times Cited: 16
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
Jia Wei, Xiaofeng Lu, Qin Liu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects
Wanting Hou, Yaqin Zhao, Hong Zhu
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15321-15321
Open Access | Times Cited: 23
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Xiaofeng Chen, Hao Xu, Xiaobing Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 14
Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
Akira Ooki, Hiroki Osumi, Koichiro Yoshino, et al.
Gastric Cancer (2024) Vol. 27, Iss. 5, pp. 907-931
Open Access | Times Cited: 12
Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study
Yuxiang Wang, Chao-ping Zhou, Da-tian Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study
Wen‐Jin Zhong, Jianan Lin, Chu‐Ying Wu, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 9
Immunotherapy and Cancer: The Multi-Omics Perspective
Clelia Donisi, Andrea Pretta, Valeria Pusceddu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3563-3563
Open Access | Times Cited: 8
Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications
Penghui Li, Xiangjie Fang, Di Huang
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
CT-Based Deep Learning Predicts Prognosis in Esophageal Squamous Cell Cancer Patients Receiving Immunotherapy Combined with Chemotherapy
Xiaoyu Huang, Yong Huang, Ping Li, et al.
Academic Radiology (2025)
Closed Access | Times Cited: 1
Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
Yuzhou Zhao, Danyang Li, Jing Zhuang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 5
Open Access | Times Cited: 6
Research progress on the immune microenvironment and immunotherapy in gastric cancer
Pei Mou, Qing-hua Ge, Rong Sheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Targeting Lysosome for Enhanced Cancer Photodynamic/Photothermal Therapy in a “One Stone Two Birds” Pattern
Quanwei Sun, Jinming Yang, Qinghua Wu, et al.
ACS Applied Materials & Interfaces (2023) Vol. 16, Iss. 1, pp. 127-141
Closed Access | Times Cited: 13
Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review
Jincheng Wang, Ti Tong, Guangxin Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial
Xiong Sun, Jianbo Lyu, Ming Yang, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 12, pp. 8157-8169
Closed Access | Times Cited: 5
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
Chen Li, Yantao Tian, Yanan Zheng, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
Daniele Lavacchi, Sara Fancelli, Eleonora Buttitta, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4877-4877
Open Access | Times Cited: 12
Perioperative immunotherapy for esophageal squamous cell carcinoma
Dan D. Wei, Jin M. Fang, Huan Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
NIR-IIb fluorescence antiangiogenesis copper nano-reaper for enhanced synergistic cancer therapy
Wenling Li, Huan Xin, Wenjuan Gao, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top